Table 2.
Results of follow-up and efficacy evaluation of IFX treatment
| Follow-up and efficacy evaluation results | N, % (Total N = 26) |
|---|---|
| Outcomes | |
| Death | 0, 0 |
| Surgery | 8, 30.8% |
| 1-year surgery-free survival | 15 of 22, 68.1% |
| 2-year surgery-free survival | 12 of 19, 63.2% |
| Surgery-free survival | 18, 69.2% |
| Fistula closure | 5, 19.2% |
| Fistula remaining | 13, 50.0% |
| IFX failure | 3, 11.5% |
| Intolerance | 1, 3.8% |
| Loss-of-response | 2, 7.7% |
| IFX-failure-free surgery-free survival | 15, 57.7% |
| Efficacy evaluation | |
| Efficacy at 3 months | |
| Remission | 12 of 24, 50.0% |
| Response | 12 of 24, 50.0% |
| Non-response | 0 of 24, 0 |
| Efficacy at 6 months | |
| Remission | 14 of 23, 60.9% |
| Response | 7 of 23, 30.4% |
| Non-response | 2 of 23, 8.7% |
| Efficacy at 24 months | |
| Remission | 6 of 8, 75% |
| Response | 1 of 8, 12.5% |
| Non-response | 1 of 8, 12.5% |